drugset / Trial / NCT04963738

A Study of JNJ-73763989 in Adult Participants With Renal Impairment

NCT04963738

Phase 1 Completed 29 enrolled Janssen Research & Development, LLC
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) of a single subcutaneous (SC) dose of JNJ-73763989 in adult participants with renal impairment compared with healthy participants with normal renal function.

Timeline

Start
2021-09-22
Primary completion
2022-10-17
Completion
2022-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-73763989 Small interfering RNA (siRNA) Subcutaneous